B16-F1 / B16-F1-luc Orthotopic Mouse Model Service for Melanoma

The B16-F1 / B16-F1-luc orthotopic mouse model for melanoma implants a melanin-producing, low-metastatic murine melanoma into the skin of immunocompetent C57BL/6 mice, where primary tumors and lung spread can be tracked non-invasively by bioluminescence. Working solely in preclinical oncology, Alfa Cytology delivers this syngeneic platform as a full service, from authenticated B16-F1 / B16-F1-luc cell supply through intradermal orthotopic inoculation, scheduled in vivo imaging with melanin-aware signal interpretation, and endpoint histopathological confirmation.

Overview of B16-F1 / B16-F1-luc Orthotopic Mouse Model for Melanoma

The B16 melanoma system is a pillar of experimental oncology. The parent tumor arose spontaneously in a C57BL/6 mouse in 1954, and in the landmark cloning experiments of Isaiah Fidler, individual clones were isolated and tested for organ-selective colonization—work that produced the entire B16 subline family. B16-F1, catalogued by ATCC as CRL-6323, is the low-passage, low-metastatic first-generation clone, in deliberate contrast to its aggressively metastatic sibling B16-F10, which was selected through repeated lung colonization cycles. The cells are adherent and epithelial-like in culture, double roughly every 22 hours, and—critically for melanoma biology—produce melanin. Engrafted in syngeneic H-2^b hosts, B16 expresses the shared melanoma antigen gp75/TRP-1, the target of the canonical TA99 antibody, and exists in a rich library of engineered formats including OVA-expressing variants for antigen-specific immunology. Like many melanomas, B16 expresses low levels of MHC class I and is weakly immunogenic, a phenotype that makes it the standard immunologically cold melanoma benchmark.

Fig 1. Tumor inoculation method. (Potez, Marine, et al., 2018)

Orthotopically, B16-F1 is implanted intradermally into the skin—its tissue of origin—where palpable tumors appear within about five days; alternative orthotopic formats include ear pinna implantation for microenvironment-focused questions and subcutaneous tail injection, which achieves 100% hematogenous and lymphatic metastasis in published syngeneic studies. Luciferase-tagged derivatives (B16-F1-luc, including the ATCC B16-F1-Luc2 reporter, CRL-6323-LUC2) enable whole-animal bioluminescence tracking of primary tumor growth and lung colonization after intravenous challenge, where inocula of 2 × 10⁵ cells seed pulmonary lesions quantifiable by lung weight and histology. One technical nuance distinguishes melanoma imaging from other tumor types: endogenous melanin absorbs bioluminescent light, so signal intensity in pigmented B16-F1 tumors systematically underestimates true burden—an interpretive caveat that study designs must account for through depigmentation strategies, calibration curves, or corroborating caliper and histological readouts. The model remains the workhorse for immunotherapy combination studies, checkpoint inhibitor benchmarking, vaccine platforms, and anti-metastatic agent evaluation in an immunocompetent setting. Figure 1 summarizes how this orthotopic system is assembled and monitored.

Cell Line Information: B16-F1 / B16-F1-luc

B16-F1 has served melanoma research for seven decades, and its characterization runs from classic tumor biology to modern sequencing. The defining attributes are summarized below.

Our Services

A B16-F1 / B16-F1-luc engagement at Alfa Cytology is run as one accountable program: verified cell banking, intradermal orthotopic inoculation with disciplined injection-site control, melanin-aware IVIS imaging with corroborating caliper and histology readouts, dosing per the client’s regimen, and a terminal package quantifying primary tumors, lung metastatic burden, and immune infiltrates.

Workflow of B16-F1 / B16-F1-luc Orthotopic Mouse Model Construction

Establishing a B16-F1 or B16-F1-luc orthotopic melanoma is a skin-focused workflow in which the intradermal injection creates a primary tumor from which vascular challenge can later model dissemination. The sequence below reflects the standard execution of this platform.

1. Cell Bank Verification and Expansion: B16-F1 or B16-F1-luc stocks are authenticated and mycoplasma-tested, then expanded in DMEM-based medium with subculture to maintain exponential growth and consistent melanin production.
2. Luciferase Calibration with Melanin Awareness (B16-F1-luc Only): Signal per cell is verified, and in vitro calibration across pigmentation levels establishes the quenching relationship that will govern in vivo signal interpretation.
3. Mouse Preparation and Randomization: C57BL/6 mice, typically 6–8 weeks old, are acclimatized, randomized by body weight, and shaved at the flank or back site under approved animal protocols.
4. Orthotopic Intradermal Inoculation: A single-cell suspension (commonly 0.5–2 × 10⁵ cells in a minimal volume) is injected strictly intradermally into the depilated skin site; correct plane placement is confirmed by a visible bleb.
5. Primary Tumor Monitoring: Tumors are palpable within about five days and measured by caliper or tracked by whole-animal bioluminescence after D-luciferin, with imaging intervals and depigmentation regimens (e.g., PTU feed where applicable) pre-specified to manage melanin quenching.
6. Treatment Administration: Test agents—checkpoint inhibitors, vaccines, targeted agents, or photothermal nanoplatforms—are dosed per the client’s schedule once tumors reach the target volume.
7. Optional Metastatic Challenge: For dissemination questions, a parallel cohort receives 2 × 10⁵ B16-F1-luc cells via tail vein, with lung colonization tracked by imaging and scored at ~4 weeks by lung weight and surface nodule counts.
8. Endpoint Analysis and Immune Profiling: At endpoint, primary tumors are excised and weighed; lungs, draining lymph nodes, and spleen are collected for ex vivo imaging, H&E confirmation of metastatic foci, and flow cytometric profiling of tumor-infiltrating lymphocytes and myeloid populations.

Fig 2. B16-F1 / B16-F1-luc orthotopic mouse model construction workflow.

Case Study-B16-F1 / B16-F1-luc Orthotopic Mouse Model Development

Alfa Cytology has executed preclinical programs on the B16-F1 / B16-F1-luc orthotopic platform for clients benchmarking checkpoint inhibitor combinations, testing vaccine and adoptive cell concepts, and evaluating anti-metastatic and photothermal strategies, delivering melanin-aware bioluminescence records, primary tumor growth curves, lung metastasis quantification, and immune-profiling-supported endpoint packages. As each engagement is configured around the client’s own therapeutic concept, study outlines and representative datasets are available upon request.

Why Choose Alfa Cytology?

Melanoma imaging has a quirk that generic CROs routinely miss: pigment eats light. Alfa Cytology’s melanin-aware imaging protocols, pigmentation-controlled study designs, and immunocompetent execution keep B16-F1 / B16-F1-luc orthotopic studies both quantitative and biologically faithful.

• Authenticated B16-F1 / B16-F1-luc banks with mycoplasma verification and pigmentation consistency checks.
• Precise intradermal orthotopic inoculation technique with correct-plane confirmation for reproducible primary tumors.
• Melanin-aware IVIS imaging with calibration curves, depigmentation regimens, and corroborating endpoints.
• Immunocompetent C57BL/6 hosts preserving the full immune context for checkpoint and vaccine studies.
• Parallel metastatic-challenge formats (tail vein) with lung weight and histology confirmation.
• Immune-profiling endpoints covering tumor-infiltrating lymphocytes and myeloid populations.

Contact Us

From checkpoint combinations to photothermal nanomedicine, Alfa Cytology can configure a B16-F1 / B16-F1-luc orthotopic study that respects both the immunology and the physics of pigmented melanoma. Contact us today to discuss study design and imaging strategy, or reach out to our team for a customized quotation.

For research use only. Not intended for any clinical use.